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REVIEW
Abstract: Events of the past decade have stimulated development of new drug formulations 
and delivery devices that have improved the efﬁ  ciency, ease of use, and environmental impact 
of inhaled drug therapy. Respimat
® Soft Mist™ Inhaler is a novel, multidose, propellant-free, 
hand-held, liquid inhaler that represents a new category of inhaler devices. The aerosol cloud 
generated by Respimat
 contains a higher fraction of ﬁ  ne particles than most pressurized metered 
dose inhalers (pMDIs) and dry powder inhalers (DPIs), and the aerosol spray exits the inhaler 
more slowly and for a longer duration than with pMDIs. This translates into higher lung drug 
deposition and lower oropharyngeal deposition, making it possible to give lower nominal 
doses of delivered drugs without lowering efﬁ  cacy. In clinical trials in patients with COPD, 
bronchodilator drugs delivered from Respimat were equally effective at half of the dose delivered 
from a pMDI. In one study of inhaler preference, Respimat was preferred over the pMDI by 
patients with COPD and other obstructive lung diseases. Respimat is a valuable addition to the 
range of inhaler devices available to the patient with COPD. 
Keywords: Respimat, COPD, inhaler, bronchodilator
Introduction
For the past 50 years, the pressurized metered-dose inhaler (pMDI) and the nebulizer 
have been the primary means of delivering inhaled drugs to patients with asthma 
and COPD. These devices can be used effectively, but are inefﬁ  cient and may be 
difﬁ  cult or cumbersome to use. Some of the limitations of these standard inhaler 
devices are accentuated in patients with COPD, especially if they are elderly or 
have severe disease. Standard pMDIs at best deposit 10%–15% of the delivered 
dose in the lungs and most of the inhaled dose is deposited in the oropharynx. To 
perform optimally, pMDIs require coordination of actuation with inhalation as well 
as a slow inspiratory ﬂ  ow rate and breath-holding (Wolff and Niven 1994). Poor 
coordination of pMDI actuation with inhalation has been shown to result in lower 
lung deposition of drug and reduced lung function response (Newman et al 2001). 
The pMDI breathing maneuver requires education and repeated instruction, and 
can be problematic for older patients with COPD. Addition of a spacer or holding 
chamber can decrease oropharyngeal drug deposition and improve lung delivery, 
but makes the system less portable. Handling of a pMDI can also be more difﬁ  cult 
if the patient has arthritis of the hands. While jet nebulizers may be popular with 
some patients with COPD, they are time-consuming, very inefﬁ  cient, and require 
cleaning. For routine use of treatment for ambulatory patients, standard jet nebulizers 
are not portable and have not been proven to offer additional efﬁ  cacy in asthma or 
COPD patients (Dolovich et al 2005). Other issues that may be prominent in an 
elderly COPD population are the confusion that arises with prescription of multiple 
inhalers with different instructions for use and also the expense of newer inhaled 
drug–device combinations.
Events of the past decade have stimulated development of novel drug 
formulations and delivery devices that have improved the efﬁ  ciency, ease of 
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use, and environmental impact of inhaled drug therapy. 
Because of deleterious effects of chloroﬂ  uorocarbon (CFC) 
propellants on the ozone layer, the Montreal Protocol 
was developed by the United Nations in 1987, banning 
substances that deplete the ozone layer (Leach 1995). 
This ban phased out the use of CFCs by 1996, although 
pharmaceutical companies had exemptions. Germany is 
the ﬁ  rst country to complete the phasing out of CFCs. 
Further developed countries will follow in the next few 
years. While the contribution of CFC inhaler propellants 
has a minute environmental impact, this ban has had a large 
effect on subsequent development of inhaler technology. 
Development of novel inhaler devices has focused on three 
areas: pMDIs with hydroﬂ  uoroalkane (HFA) propellants, 
dry powder inhalers (DPIs), and liquid multidose spray 
devices that do not require propellants. There are 
advantages and drawbacks to all three types of drug–device 
systems. HFA-pMDIs generate aerosols that exit at lower 
velocity and may contain smaller particles. This may 
improve lung deposition, but these devices still require 
good coordination and slow inhalation. DPIs require 
high inspiratory ﬂ  ow rates and may not work effectively 
in a patient with severe COPD. DPIs also are associated 
with high oropharyngeal deposition (Fink 2000) and the 
drug powder can be sensitive to moisture. Respimat
® 
Soft Mist™ Inhaler (Boehringer Ingelheim, Ingelheim, 
Germany) is a novel, multidose, propellant-free, hand-held 
liquid inhaler that represents a new category of inhaler 
devices. “Soft Mist” is used to describe the mechanism of 
aerosol generation and the qualities of the aerosol cloud. 
The aerosol plume generated by Respimat
 travels much 
slower and lasts much longer than aerosol clouds from 
other devices, properties that improve delivery and make 
this device a valuable addition to inhalers available for 
inhalation therapy to COPD patients. 
Description and design of device
Respimat
 is a hand-held inhaler with a hinged cap that is 
similar in size to pMDIs and some DPIs (Figure 1). Figure 
2 shows a schematic of the device (Dalby et al 2004). 
Medication is stored as a solution in the drug cartridge, 
an aluminum cylinder containing a double-walled, plastic, 
collapsible bag that contracts as the solution is used. The 
solution may be formulated with either ethanol or water, 
with benzalkonium chloride and ethylene diamine tetra-
acetic acid (EDTA) added as preservatives. The amount of 
preservatives in each puff is extremely low: approximately 
0.44 μg for benzalkonium chloride and 2.2 μg for EDTA. 
Tests on used cartridges have shown that patient use does 
not cause bacterial contamination of the solution in the 
cartridge. The ﬁ  rst marketed product delivers 120 actuations 
and has a dose indicator, which is a color-coded gauge 
marked in increments of 30 doses. This indicator gives an 
estimate of doses remaining but does not count individual 
doses. After 120 actuations have been delivered, a locking 
mechanism prevents further use by preventing twisting of 
the base so that no further doses can be actuated. Respimat 
does not require a spacer, a battery, or outside power source. 
Twisting the base of the device 180 degrees compresses a 
spring and provides mechanical power to aerosolize the dose 
of drug and also transfers a metered dose of drug (usually 
10–15 μL) from the drug cartridge through a capillary tube to 
the pump cylinder. When the dose-release button is pushed, 
the energy from the compressed spring forces the drug 
through a nozzle system called the “uniblock” (Figure 2). 
The uniblock consists of a silicone wafer bonded to a glass 
plate and measures approximately 2 x 2.5 mm. Channels 
are etched into the silicon wafer using a technique derived 
from microchip technology and these channels feed into the 
nozzle outlet.
Production of inhalation mist
Actuation of the Respimat dose-release button utilizes 
the mechanical energy from the spring to force the 
metered drug solution through the channels in the 
uniblock, producing two ﬁ  ne jets of liquid at the outlet 
that converge at a predetermined angle to form the aerosol 
cloud (Spallek et al 2002). This cloud contains an aerosol 
Figure 1 Respimat
® Soft Mist Inhaler™. Reprinted from Dalby R, Spallek M, 
Voshaar T. 2004. A review of the development of Respimat
® Soft Mist Inhaler™. 
Int J Pharm, 283:1–9. Copyright © 2004, with permission from Elsevier.International Journal of COPD 2006:1(3) 253
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with a fine-particle fraction (particles smaller than 5.8 μm) 
at least twice as high as most pMDIs and DPIs, which 
would allow a higher proportion of the emitted dose to be 
delivered to the lungs and less to the oropharynx. The fine 
particle fraction is higher for ethanolic formulations than 
for aqueous formulations, with a mass median aerodynamic 
diameter of 2.0±0.4 μm for aqueous solutions and 
1.0±0.3 μm for ethanolic solutions (Zierenberg 1999). 
The fine-particle fraction is approximately 66% for 
an aqueous drug solution and 81% for an ethanolic 
solution. The “soft mist” moves more slowly and has a 
more prolonged duration than the aerosol cloud from a 
pMDI. Hochrainer et al (2005) have compared Respimat
 
aerosol velocity and spray duration with that of CFC-
pMDIs and HFA-pMDIs via video-recording (Figure 3). 
The velocity of the aerosol from Respimat
 was between 
one-sixth and one-tenth of that from the CFC-pMDIs 
and two of the HFA-pMDIs and approximately one-
third of the velocity of the “slower” HFA-pMDIs. The 
mean velocity of the aerosol cloud measured at a 10 cm 
distance from the nozzle was 0.8 m/s for Respimat and 
2.0–8.4 m/s for pMDIs, while the mean duration was 
1.5 s and 0.15–0.36 s, respectively. The combination of 
smaller particle size, lower velocity, and longer duration 
of the aerosol cloud implies that there would be improved 
coordination of inhalation with actuation, higher lung 
deposition, and lower oropharyngeal deposition compared 
with pMDIs.
After receiving a new Respimat inhaler, a patient 
must insert the cartridge by removing the transparent 
base and pushing the cartridge into the inhaler until 
it clicks into place. The dose is loaded by holding the 
inhaler in an upright position and turning the base 180 
degrees until it clicks. The inhaler requires priming prior 
to ﬁ  rst use by actuating until an aerosol cloud is visible 
and then completing three more actuations. Spray content 
uniformity measurements show priming actuations 
necessary to achieve 100% of target volume and also 
show spray uniformity over 120 doses without “tail-off” 
effect (Spalleck 2002). Priming with actuation of one dose 
is recommended after a week of no use, and full priming 
is recommended after 21 days of no use. Instructions for 
inhalation direct the patient to breathe out slowly and 
deeply and close lips around the end of the mouthpiece 
while holding the inhaler in a horizontal position. The 
dose-release button should be pushed while the patient 
takes a slow, deep breath in through their mouth and a 
10-second breath-hold is recommended. The dose can be 
administered to the patient with the inhaler held in any 
position.
Mouthpiece
Uniblock
Dose-release button
Capillary tube
Upper housing
Transparent base
Spring
Cartridge
Glass
Silicon wafer
Filter structure
Nozzle outlet
Figure 2 Schematic of Respimat
® Soft Mist Inhaler™ showing the details of the uniblock. Reprinted from Dalby R, Spallek M, Voshaar T. 2004. A review of the 
development of Respimat
® Soft Mist Inhaler™. Int J Pharm, 283:1–9. Copyright © 2004, with permission from Elsevier.International Journal of COPD 2006:1(3) 254
Anderson
Mist deposition in lungs
Improved lung deposition of drug aerosols from the 
Respimat
 has been demonstrated by several studies using 
radiolabeled drug particles and gamma scintigraphy 
(Newman et al 1996, 1998; Steed et al 1997). This group 
of studies in healthy nonsmoking volunteers used either 
fenoterol, which was formulated in an aqueous medium, or 
ﬂ  unisolide, formulated in 96% ethanol. In one study with 
ﬂ  unisolide, the mean whole-lung deposition from Respimat 
(40% of the metered dose) was significantly higher 
than from the pMDI (15%) or pMDI plus spacer (28%) 
(Newman et al 1996). A follow-up study using ﬂ  unisolide 
and a ﬁ  nal prototype Respimat showed signiﬁ  cantly more 
lung deposition with Respimat compared with pMDI 
plus spacer (45 vs 26%) (Newman et al 1998). In this 
same study, mean whole-lung deposition of fenoterol was 
signiﬁ  cantly greater when delivered by Respimat (39%) 
than via pMDI (11%) or pMDI plus spacer (10%). In both 
of these studies in normal subjects, the oropharyngeal 
deposition was signiﬁ  cantly lower with Respimat than 
with pMDI (approximately 40% vs 70%), but not as low 
as with pMDI plus spacer. 
A more recent investigation has compared lung deposition 
of inhaled steroids in mild to moderate asthmatic subjects 
using Respimat, Turbuhaler, and a pMDI (Pitcairn et al 2005). 
Respimat contained budesonide solution, the Turbuhaler 
contained budesonide dry powder, and the pMDI contained 
beclomethasone dipropionate; the Turbuhaler inhalations 
were performed at either 60 or 30L/m. Results for deposition 
amounts are shown in Table 1 and also Figure 4. Mean whole-
lung deposition of drug from Respimat was signiﬁ  cantly 
greater than that from Turbuhaler DPI at fast or slow inhaled 
ﬂ  ow rates, or from the pMDI. The deposition pattern within 
the lungs was more peripheral for the Respimat than for the 
Turbuhaler. These data in normal and asthmatic subjects 
would predict that lower doses of drugs via the Respimat 
would provide equal efﬁ  cacy to higher doses delivered via 
the pMDI or Turbuhaler. 
Effectiveness and safety of device
Currently, the Respimat is marketed with a combination 
of ipratropium bromide (IB) and fenoterol hydrobromide 
(FEN) (Berodual
® Respimat) and was launched in Germany 
in January 2004. Five clinical studies have been performed 
with Berodual Respimat in patients with COPD and in 
adults and children with asthma (reviewed in Kässner et al 
2004). A pivotal Phase III, multicenter, parallel-group study 
of 892 patients with moderate to severe COPD compared 
IB/FEN via Respimat
 with a CFC-pMDI (Kilfeather et al 
2004). Patients were randomized to one of ﬁ  ve treatment 
arms: Respimat containing IB 10 μg/FEN 25 μg, Respimat 
containing IB 20 μg/FEN50 μg, pMDI containing IB 20 μg/
FEN50 μg, Respimat placebo, or pMDI placebo four times 
daily for 12 weeks. The primary efﬁ  cacy endpoint was the 
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Figure 3 (a) Mean aerosol spray velocities at 10 cm from nozzle for Respimat
® 
and various CFC- and HFA-pMDIs. (b) Mean spray duration for the devices. 
Reprinted from Hochrainer D, Hölz H, Kreher C, et al. 2005. Comparison of the 
aerosol velocity and spray duration of Respimat
® Soft Mist Inhaler™ and pres-
surized metered dose inhalers. J Aerosol Med, 18:273–82. Copyright © 2005, with 
permission from Mary Ann Liebert, Inc. 
Abbreviations: CFC, chloroﬂ  uorocarbon; HFA, hydroﬂ  uoroalkane; pMDI, 
pressurized metered dose inhaler; SMI, Soft Mist™ inhaler. International Journal of COPD 2006:1(3) 255
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Table 1 Mean percentage dose of steroid deposited (and range) for different devices in asthmatic subjects (modiﬁ  ed from Pitcairn 
et al 2005)
   Respimat
®   Turbuhaler
®     Turbuhaler
®   pMDI 
   (fast  ﬂ  ow)   (slow  ﬂ  ow)   
Lungs (%)   52  (46–57)   29  (24–33)   18  (14–22)   9  (6–12) 
Oropharynx (%)   19  (15–24)   49  (44–55)   41  (35–46)   82  (78–86) 
Device (%)   18  (14–22)   21  (17–26)   40  (35–46)   9  (6–12) 
Figure 4 Typical scintigraphic images for Respimat
®, Turbuhaler
® DPI at slow and fast inhaled ﬂ  ow rates, and CFC-pMDI. Reprinted from Pitcairn G, Reader S, Pavia D, 
et al. 2005. Deposition of corticosteroid aerosol in the human lung by Respimat
® Soft Mist™ Inhaler compared with deposition by metered dose inhaler or by Turbuhaler
® 
dry powder inhaler. J Aerosol Med, 18:264–72. Copyright © 2005, with permission from Mary Ann Liebert, Inc.
Abbreviations: CFC, chloroﬂ  uorocarbon; DPI, dry powder inhaler; pMDI, pressurized metered dose inhaler; SMI, Soft Mist™ inhaler.
 
Respimat SMI 
Turbohaler DPI - fast 
Turbohaler DPI - slow 
pMDIInternational Journal of COPD 2006:1(3) 256
Anderson
average change from pre-dose in FEV1 over the ﬁ  rst hour 
after dose administration on day 85 of treatment and the 
study was powered for non-inferiority. The bronchodilator 
response to IB/FEN on day 85 showed that the 20/50 μg 
dose via Respimat was not inferior to the 40/100 μg dose 
via CFC-pMDI (Figure 5).
Four trials of IB/FEN via Respimat have been 
conducted in patients with asthma (thee in adults and on 
in children). Two of these were proof-of-concept, Phase 
II, dose-ranging and cumulative dose studies in adults with 
asthma (Kunkel et al 2000; Goldberg et al 2001). In the 
dose-ranging study (Goldberg et al 2001), ﬁ  ve different 
doses of IB/FEN (from 5/12.5 μg to 80/200 μg) were 
used and showed a log-linear dose response for average 
increase in FEV1 up to 6 hours. Responses to IB/FEN doses 
of 5/12.5 and 10/25 μg administered via Respimat were 
closest or slightly superior to that for the IB/FEN dose 
of 40/100 μg delivered with CFC-pMDI. Therapeutic 
equivalence could not be demonstrated statistically in 
this study due to higher-than-expected variability. The 
cumulative dose study in adults with asthma (Kunkel 
et al 2000) concluded that IB/FEN delivered by Respimat 
was as effective as the CFC-pMDI at half the cumulative 
dose. Two Phase III studies were done comparing IB/FEN 
via Respimat and CFC-pMDI in adults and children with 
asthma (Vincken et al 2004; von Berg et al 2004). These 
studies concluded that delivery by Respimat instead of a 
CFC-pMDI allows a two- to four-fold reduction in dosage 
of IB/FEN while achieving similar efﬁ  cacy. These trials 
in COPD and asthmatic subjects provide evidence in 
favor of the deposition experiment predictions that IB/FEN 
delivered by Respimat can be given at a reduced dosage 
(one-fourth to one-half) compared with that given by 
CFC-pMDI without any loss of efﬁ  cacy.
The only other clinical trial published to date using 
Respimat in COPD patients was a cumulative dose 
study of ipratropium bromide compared with delivery 
via pMDI (Iacono et al 2000). This was a three-period 
cross-over study in 36 patients in which two dosages 
of IB by Respimat were used (10 and 20 μg per puff) 
compared with 20 μg per puff via CFC-pMDI. The study 
found greater bronchodilation from half the cumulative 
dose of IB by Respimat compared with the pMDI. 
There have been two Phase II published comparative 
trials using FEN, given alone to asthmatic subjects 
via Respimat and CFC-pMDI (van Noord et al 2000; 
Vincken et al 2003), and again showing the ability to use 
reduced doses with the Respimat. There have also been 
clinical trials conducted examining clinical efﬁ  cacy and 
safety of tiotropium bromide delivered by Respimat in 
COPD subjects, but these have not been published.
Safety analysis of the five clinical trials using IB/
FEN in the Respimat showed an adverse event profile 
similar to the CFC-pMDI. In one of the Phase II studies 
(Kunkel et al 2000), the 320/800 μg dose given with 
Respimat was associated with a slightly higher incidence 
of headache, nervousness, and tremor than the same dose 
by pMDI. This may have been due to slightly increased 
β2-adrenergic stimulation and cholinergic blockade with 
the greater drug delivery to the lungs by the Respimat. 
In the Phase III studies, the adverse-event profiles of the 
10/25 and 20/50 μg doses of IB/FEN via Respimat were 
comparable with that of the 40/100 μg dose via CFC-
pMDI, and the frequency of adverse events thought to be 
treatment-related was low across all groups. Because of 
the use of the preservatives benzalkonium chloride and 
EDTA in bronchodilator preparations in the Respimat, 
there have been questions about the possibility of 
paradoxical bronchoconstriction with Respimat. This 
has been analyzed in both the Phase II and Phase III data 
sets for IB/FEN and either drug alone, and incidence 
of paradoxical bronchoconstriction was not found to 
be increased compared with CFC-pMDI (Koehler et al 
2004; Hodder et al 2005). For the COPD and asthma 
patients in this analysis, there were no observed episodes 
of bronchospasm following administration of active 
drug or placebo via the Respimat. The incidence of 
asymptomatic falls in FEV1 >15% from baseline after 
Respimat use was 0%–2.8% in the active treatment group 
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Figure 5 Change in FEV1 from pre-dose value in ﬁ  rst 60 minutes after dosing on 
day 85 for IB/FEN delivered by Respimat
® (two doses) and by pMDI compared 
with placebo devices in COPD patients. Reprinted from Kilfeather SA, Ponitz HH, 
Beck E, et al. 2004. Improved delivery of ipratropium bromide/fenoterol from 
Respimat
® Soft Mist™ Inhaler in patients with COPD. Respir Med, 98:387–97. 
Copyright © 2004, with permission from Elsevier.
Abbreviations: MDI, metered dose inhaler; SMI, Soft Mist™ inhaler.International Journal of COPD 2006:1(3) 257
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and 0%–7.6% in the placebo group and was no different 
than that measured after CFC p-MDI.
Patient-focused perspectives 
such as correct inhaler use, 
patient satisfaction–acceptability, 
compliance, and uptake
Many patients lack coordination for the split-second timing 
required between beginning a slow inhalation and activation 
of a pMDI (McFadden 1995; Fink and Rubin 2005). 
Asynchronous actuation can greatly reduce the amount of 
medication inhaled from a pMDI (Wilkes et al 2001) and can 
also reduce clinical effect of the inhaled drug (McFadden 
1995; Newman et al 2001). One study showed that incidence 
of critical errors in pMDI use were signiﬁ  cantly higher in 
COPD patients (26%) compared with asthma patients (13%) 
(Melani et al 2004). Problems with hand–breath coordination 
can be addressed by use of breath-actuated pMDIs, pMDIs 
plus spacer devices, DPIs, or nebulizers (Newman 2005). 
Newer HFA-pMDIs create aerosols that exit at a lower 
velocity than CFC-pMDIs and may have a smaller particle 
size, both factors which may help overcome problems 
with poor coordination. Like the pMDI, Respimat is also 
a press and breathe device and requires some coordination 
of actuation and inhalation. Respimat demonstrates lower 
aerosol velocity and longer spray duration that either CFC 
or HFA pMDIs, which should allow patients to coordinate 
actuation and breathing more easily. The deposition data 
show that Respimat deposits signiﬁ  cantly more drug in the 
lungs of asthmatic patients than the Turbuhaler DPI or a 
CFC-pMDI in the setting of optimal inhalation technique. 
To date, no studies have been published that examine drug 
deposition from the Respimat in subjects with COPD or 
assess deposition and efﬁ  cacy of Respimat in patients with 
poor inhalation technique.
In a clinical trial comparing IB/FEN via Respimat or an 
HFA-pMDI in 245 patients with COPD, asthma or mixed 
disease, correct assembly, and inhaler technique were 
assessed after training at the beginning of each treatment 
period (Schurmann et al 2005). Patients were given up 
to five attempts to demonstrate satisfactory technique 
and were scored on seven different device handling and 
breathing tasks. At the beginning of each treatment period, 
96.4% could demonstrate satisfactory inhaler technique 
with Respimat by the ﬁ  nal attempt, compared with 98% 
of patients with HFA-pMDI. The proportion of patients 
achieving a score of 7 at the ﬁ  rst attempt was higher for 
HFA-pMDI (80%) than for Respimat (48%), perhaps due to 
the novelty of the Respimat device. While patients required 
more training for good technique with Respimat, patients 
retained good technique with Respimat after 7 weeks (97%), 
compared with 94% in th HFA-pMDI group. Most patients 
found the Respimat easy to assemble and only one patient 
was unable to assemble the device.
With the multitude of inhaler devices now available, 
there has been increased interest in the assessment of patient 
preference and satisfaction, as preference for a particular 
medication or inhaler device may be associated with 
improved adherence with therapeutic regimens. Boehringer 
Ingelheim developed and validated a patient satisfaction 
and preference questionnaire for inhalation devices to 
better assess satisfaction with the Respimat compared with 
other devices (Kozma et al 2005). The Patient Satisfaction 
and Preference Questionnaire (PASAPQ) was developed 
using published papers, focus groups, and expert opinion. 
The ﬁ  nal questionnaire contains 14 satisfaction items, 
including a global satisfaction question, as well as one 
preference question and one question on willingness to 
use the device in the future. The satisfaction items were 
grouped into two domains: performance (seven items) 
and convenience (six items). Of all device satisfaction 
instruments that have been used in clinical trials, only the 
PASAPQ has a published validation and determination of 
minimally important difference, which is very important 
for discriminating the degree of difference that is clinically 
signiﬁ  cant. 
The PASAPQ was used in a study speciﬁ  cally designed to 
examine preference for and satisfaction with inhaler devices in 
patients with COPD, asthma, or mixed disease in a crossover 
study of IB/FEN delivered via Respimat vs HFA-pMDI 
(Schürmann 2005). The questionnaire was administered 
after each 7-week treatment period and of the 201 out of 224 
subjects expressing a preference, 81% preferred Respimat. 
Of the 44 patients who had concomitant diagnoses that might 
affect inhaler handling, such as eye problems or arthritis, 
89% preferred Respimat. This preference was not affected 
by type of lung disease or age. Patients were more willing to 
continue to use Respimat and mean ratings for 13 of 15 items 
in the satisfaction questionnaire were signiﬁ  cantly higher for 
Respimat. There were no differences between the inhalers 
for efﬁ  cacy measures such as peak expiratory ﬂ  ow, rescue 
inhaler use, and symptom scores. Taking device preference 
and satisfaction into account when choosing an inhaler device 
may be associated with improved clinical outcomes, but this 
has not been proven to date.International Journal of COPD 2006:1(3) 258
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Conclusions – role in therapy
Respimat represents a novel approach to the delivery of 
inhaled drugs and overcomes some of the limitations of 
pMDIs, DPIs, and nebulizers. It is portable, propellant-free, 
uses mechanical energy for actuation, and does not require 
cumbersome spacers or holding chambers. Unlike some 
DPIs, optimal aerosol generation does not depend on high 
inspiratory ﬂ  ow rates. Respimat produces an aerosol with a 
greater ﬁ  ne-particle fraction than most pMDIs, DPIs, and 
nebulizers and the aerosol spray produced exits the inhaler 
more slowly and lasts for a longer time. This translates 
into higher lung drug deposition and lower oropharyngeal 
deposition than the pMDI and also Turbuhaler DPI. For some 
drug formulations, therapeutic ratio could be improved with 
Respimat, by offering higher lung deposition with lower 
oropharyngeal deposition and lower nominal dosing. It is 
also possible that drug delivery and efﬁ  cacy will be improved 
with Respimat in those patients who have difﬁ  culties in 
actuating and coordinating inhalation when using a pMDI, 
but the device still requires some degree of hand–breath 
synchronization. In clinical trials in patients with COPD, 
bronchodilator drugs delivered from Respimat were equally 
effective at half of the dose delivered from a pMDI. In one 
study of inhaler preference, Respimat was preferred over 
the pMDI by patients with COPD and other obstructive lung 
diseases. It is not clear, however, if preference for the device 
will lead to improved adherence and clinical outcomes. 
Currently, Respimat is available in Germany containing 
a combination of ipratropium bromide and fenoterol. As 
availability increases, usage of Respimat will likely be affected 
by available drugs and also by cost. Respimat is a novel and 
valuable addition to the range of inhaler devices available 
to the patient with COPD. It overcomes the challenge of 
hand–breath coordination that may be a problem for patients 
when using a pMDI and does not require generation of high 
inspiratory ﬂ  ow rates required for some DPIs. Respimat also 
makes it possible to give lower nominal doses of delivered 
drugs without decreasing efﬁ  cacy. A continuing challenge 
in this population of patients, however, is the expense and 
confusion engendered by use of multiple inhaler devices. 
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